Evidence map›Paper›PMID 35666645›Full record

ReviewCancer cytopathology2022

Multiplexed single-cell analysis of FNA allows accurate diagnosis of salivary gland tumors.

Juhyun Oh, Tae Yeon Yoo, Talia M Saal, Lisa Tsay, William C Faquin, Jonathan C T Carlson, Daniel G Deschler, Sara I Pai, Ralph Weissleder

Open access · hybridAbstract readReview
In one paragraph

Review in Cancer cytopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Juhyun OhCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-4492-6978
Tae Yeon YooDepartment of Systems Biology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8145-1051
Talia M SaalCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-5472-2143
Lisa TsayCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.
William C FaquinDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9043-7171
Jonathan C T CarlsonCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-4139-9057
Daniel G DeschlerDepartment of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts.ORCID 0000-0003-2680-8035
Sara I PaiCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0002-6341-9971
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts.ORCID 0000-0003-0828-4143
Harvard University · USMassachusetts General Hospital · USMassachusetts Eye and Ear Infirmary · US

Funding

The role of microvesicles in giloma virotherapyP01CA069246 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAREST, ALAIN · 1996 to 2021
$30.9M
Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI MEMPEL, THORSTEN ROMAN · 2019 to 2023
$8.4M
FAST-FNA immune cell profiling in HNSCCR01CA257623 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FAQUIN, WILLIAM CLAY, WEISSLEDER, MD, PHD, RALPH · 2021 to 2025
$3.3M
Imaging tumor associated macrophage (TAM) functionR01CA206890 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PITTET, MIKAEL, WEISSLEDER, MD, PHD, RALPH · 2017 to 2021
$1.9M
NCI NIH HHS P01 CA069246NCI NIH HHS P01CA069246NCI NIH HHS P01 CA240239NCI NIH HHS P01CA240239NCI NIH HHS R01 CA206890NCI NIH HHS R01CA206890NCI NIH HHS R01 CA257623NCI NIH HHS R01CA257623
6 · The paper itself

Abstract

Diagnosing salivary gland tumors (SGTs) through fine-needle aspiration (FNA) biopsies is challenging due to the overlapping cytomorphologic features between benign and malignant tumors. The authors developed an innovative, multiplexed cycling technology for the rapid analyses of single cells obtained from FNA that can facilitate the molecular analyses and diagnosis of SGTs. Antibodies against 29 protein markers associated with 7 SGT subtypes were validated and chemically modified via custom linker-bio-orthogonal probes (FAST). Single-cell homogenates and FNA samples were profiled by FAST cyclic imaging and computational analysis. A prediction model was generated using a training set of 151,926 cells from primary SGTs (N = 26) and validated on a separate cohort (N = 30). Companion biomarker testing, such as neurotrophic tyrosine receptor kinase (NTRK), was also assessed with the FAST technology. The FAST molecular diagnostic assay was able to distinguish between benign and malignant SGTs with an accuracy of 0.86 for single-cell homogenate samples and 0.88 for FNA samples. Profiling of multiple markers as compared to a single marker increased the diagnostic accuracy (0.82 as compared to 0.65-0.74, respectively), independent of the cell number sampled. NTRK expression was also assessed by the FAST assay, highlighting the potential therapeutic application of this technology. Application of the novel multiplexed single-cell technology facilitates rapid biomarker testing from FNA samples at low cost. The customizable and modular FAST-FNA approach has relevance to multiple pathologies and organ systems where cytologic samples are often scarce and/or indeterminate resulting in improved diagnostic workflows and timely therapeutic clinical decision-making.

Indexed as

Salivary Gland NeoplasmsSingle-Cell AnalysisBiopsy, Fine-NeedleHumansReceptor Protein-Tyrosine KinasesRetrospective StudiesSensitivity and SpecificityReceptor Protein-Tyrosine Kinasesbiomarkersfine-needle biopsymolecular diagnosticsalivary gland tumorsingle-cell analysis

Identifiers

PMID35666645
PMCPMC9542730
OpenAlexW4281774152

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.